SEC Form 4 · accession 0001722024-18-000010

CONSTELLATION PHARMACEUTICALS INC · CNST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jul 23, 2018

Accepted (ET)

Jul 23, 2018 · 4:54 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001434418

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock^F1,F2	Jul 23, 2018	C	149,637	—	A	149,637	D
Common stock	Jul 23, 2018	P	66,667	$15.00	A	216,304	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series B convertible preferred stock^F3,F1	—	Jul 23, 2018	C	208,333	D	—	—	Common stock	18,923	D
Series D convertible preferred stock^F3,F1	—	Jul 23, 2018	C	10,454	D	—	—	Common stock	949	D
Series E convertible preferred stock^F3,F2	—	Jul 23, 2018	C	111,111	D	—	—	Common stock	12,976	D
Series E-1 convertible preferred stock^F3,F1	—	Jul 23, 2018	C	285,714	D	—	—	Common stock	25,952	D
Series F convertible preferred stock^F3,F1	—	Jul 23, 2018	C	1,000,000	D	—	—	Common stock	90,837	D

F1Each share of Series B, Series D, Series E-1, and and Series F preferred stock was convertible into the Issuer's common stock at a ratio of 11.009 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2Each share of Series E preferred stock was convertible into the Issuer's common stock at a ratio of 8.5626 shares of preferred stock to 1 share of common stock, and converted automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F3Not applicable.